Melissa J Barber
Biographic Data
| ID | 9066444 |
|---|---|
| NAME | Melissa J Barber |
| GIVEN NAMES | Melissa J |
| FAMILY NAME | Barber |
| SIGNATURE | BARBER M J |
| AFFILIATIONS | Transparency International |
| ORCID | 0000-0003-3646-9428 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2024 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimens
Clinical trials are considered to be the largest contributor to pharmaceutical development costs. However, public disclosure of the costs of individual clinical trials is rare. Médecins Sans Frontières (MSF) sponsored a phase 2b-3 randomised controlled trial (TB-PRACTECAL), which identified a new treatment regimen for drug-resistant TB. We aimed to analyse the costs of undertaking a pivotal clinical trial conducted in relatively low-resource heal…
Technology transfer, intellectual property, and the fight for the soul of WHO
Debates over the scope, terms, and governance of technology transfer–the sharing of essential technical information, know-how, and materials needed to manufacture a health product–are prominent and controversial in international health diplomacy. These debates have become focal points in recent contentious negotiations to amend the International Health Regulations (IHR) and draft a global Pandemic Agreement. While some countries advocate for auto…
No prominent works on this page.
Technology transfer, intellectual property, and the fight for the soul of WHO
Debates over the scope, terms, and governance of technology transfer–the sharing of essential technical information, know-how, and materials needed to manufacture a health product–are prominent and controversial in international health diplomacy. These debates have become focal points in recent contentious negotiations to amend the International Health Regulations (IHR) and draft a global Pandemic Agreement. While some countries advocate for auto…
Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimens
Clinical trials are considered to be the largest contributor to pharmaceutical development costs. However, public disclosure of the costs of individual clinical trials is rare. Médecins Sans Frontières (MSF) sponsored a phase 2b-3 randomised controlled trial (TB-PRACTECAL), which identified a new treatment regimen for drug-resistant TB. We aimed to analyse the costs of undertaking a pivotal clinical trial conducted in relatively low-resource heal…
Pharmaceutical Economics and Policy (2 works) · Accounting (1 work) · Bedaquiline (1 work) · Biomedical Ethics and Regulation (1 work) · Biosimilars and Bioanalytical Methods (1 work) · Biotechnology and Related Fields (1 work) · Business (1 work) · Clinical trial (1 work) · Corporate governance (1 work) · Cost effectiveness (1 work)